ALMIRALL, S.A. «...678910...» Page 8 out of 16 30/03/2022 08:06 ALMIRALL, S.A. Other relevant information Presentation of 16 weeks data for Lebrikizumab ADvocate 1 & 2 Phase 3 studies: Webcast with analysts and institutional investors + Presentation Register number: 15269 26/03/2022 14:21 ALMIRALL, S.A. On business and financial situation 16 weeks data for Lebrikizumab ADvocate 1 & 2 Phase 3 studies has been announced today at the American Academy of Dermatology (AAD) Annual Meeting Register number: 15183 21/02/2022 07:00 ALMIRALL, S.A. Annual financial reports and audit reports La sociedad remite el Informe Financiero Anual del ejercicio 2021 Register number: 14138 21/02/2022 06:18 ALMIRALL, S.A. Announcement of general shareholders’ meeting Convocatoria de la Junta General Ordinaria de Accionistas de la Sociedad Register number: 14137 21/02/2022 06:15 ALMIRALL, S.A. Annual report on directors´ remunerations La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del Ejercicio 2021 Register number: 14136 21/02/2022 06:13 ALMIRALL, S.A. Annual corporate governance report La sociedad remite el Informe Anual de Gobierno Corporativo del ejercicio 2021 Register number: 14135 21/02/2022 06:05 ALMIRALL, S.A. Half-yearly financial reports and audit reports/limited audit review La sociedad remite información financiera del segundo semestre de 2021 Register number: 14134 21/02/2022 06:03 ALMIRALL, S.A. Other relevant information A webcast with analysts and institutional investors FY 2021 Register number: 14133 11/01/2022 10:12 ALMIRALL, S.A. Other relevant information Presentation: 40th Annual J.P. Morgan Healthcare Conference 2022 Register number: 13560 05/01/2022 07:58 ALMIRALL, S.A. Other relevant information Transfer of global rights for Eklira and Duaklir to Covis Pharma completed Register number: 13482 Related to communication no. 12510 dated 01/11/2021 (08:01) Page 8 out of 16 «...678910...»
